Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Aragon Pharmaceuticals

Explore full profile

Asthma Research Studies Now Enrolling

San Diego, United StatesFounded 2009Biotech & Life Sciences
Valuation $1–2.5B Last recorded · 2013
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Aragon Pharmaceuticals and the history behind them.

About Aragon Pharmaceuticals

Aragon Pharmaceuticals is a specialized company operating in the healthcare sector, focusing on clinical research and the development of new treatments for asthma and allergies. The company primarily serves patients who suffer from these conditions and are looking for innovative treatment options. Aragon Pharmaceuticals operates in the pharmaceutical and biotechnology market, which is a highly regulated and research-intensive industry.

The business model of Aragon Pharmaceuticals revolves around conducting clinical research studies. These studies are essential for the development of new medications and treatments. The company recruits qualified volunteers to participate in these studies, offering them investigational medications under the supervision of experienced doctors and research professionals. Participants may receive either the investigational medication or a placebo (an inactive substance) during the study.

Aragon Pharmaceuticals makes money through several channels. Firstly, it may receive funding from pharmaceutical companies and other organizations interested in developing new treatments. Secondly, it may receive grants and support from healthcare foundations and institutions that support medical research. Additionally, the company may generate revenue by licensing its research findings and developed treatments to larger pharmaceutical companies.

The company also engages with its clients through a bi-monthly e-newsletter, which provides valuable information on managing asthma and allergies, as well as sharing success stories from patients. This helps in building a community and maintaining a connection with its target audience.

In summary, Aragon Pharmaceuticals is dedicated to advancing medical research in the field of asthma and allergies, providing innovative treatment options, and supporting patients through clinical studies.

Source: Dealroom company data

At a glance

Founded
2009
Headquarters
San Diego, United States
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • OrbiMed
  • The Column Group
  • Aisling Capital

Series B and later1 investor entered at this stage

  • venBio Partners
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Patents

Estimated portfolio value
$98M

38 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Aragon Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aragon Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.